Zhongya Wang

Mrs. Zhongya Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Radiology
Verified
Journal Article
Closed access
FRFlorian Rieder
Florian Rieder
MBMark E. Baker
Mark E. Baker
DBDavid H. Bruining
David H. Bruining
JFJeff L. Fidler
Jeff L. Fidler
EEEric C. Ehman
Eric C. Ehman
FCfor the Stenosis Therapy and Anti-Fibrosis Research (STAR) Consortium
for the Stenosis Therapy and Anti-Fibrosis Research (STAR) Consortium
Stricture length, maximal stricture wall thickness, and maximal associated small bowel dilation at MR enterography can reliably assess Crohn disease stricture severity and serve as eligibility and efficacy criteria in clinical trials.

1 August 2024 in Radiology
Verified
Journal Article
Closed access
FRFlorian Rieder
Florian Rieder
CMChristopher Ma
Christopher Ma
JHJurij Hanžel
Jurij Hanžel
JFJoel G. Fletcher
Joel G. Fletcher
MBMark E. Baker
Mark E. Baker
FCfor the Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium
for the Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium
Maximal associated small bowel dilation, stricture length, and maximal stricture wall thickness at CT enterography can reliably describe Crohn disease stricture severity and serve as eligibility or efficacy criteria in antistricture therapy trials.

13 January 2025 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
DNDmitry Nevozhay
Dmitry Nevozhay
RRRonald Rauch
Ronald Rauch
ZWZhongya Wang
Zhongya Wang
KSKonstantin V. Sokolov
Konstantin V. Sokolov
A statistical meta-analysis of gold nanoparticles reveals non-linear interactions. The optimal design (diameter ≤ 40 nm and PEG ≥ 5 kDa) maximizes blood circulation, providing evidence-based guidelines for enhanced nanoparticle design in biomedicine.

22 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AGAyush Gandhi
Ayush Gandhi
RJRebecca Jeun
Rebecca Jeun
ZWZhongya Wang
Zhongya Wang
SKSonya Khan
Sonya Khan
CBConor Best
Conor Best
STSonali Thosani
Sonali Thosani
Background/Objectives: Diabetic ketoacidosis (DKA) is a life-threatening emergency resulting in significant morbidity and health care utilization. The most common cause of DKA in the general population is insulin nonadherence, but limited data exists on precipitating factors for DKA in cancer patients. In this study, we characterize the demographic and clinical characteristics of hospitalized patients with DKA at our comprehensive cancer center. Methods: This single-center retrospective study evaluated 91 patients with 94 admissions for DKA at our institution between January 2019 and December 2021. Demographic, clinical, and biochemical data were obtained from a review of the electronic medical record. Patient characteristics were summarized using descriptive statistics for continuous variables and categorical variables. Results: Of the 91 patients, 21% of patients (n = 19) had underlying type 1 diabetes, 49% of patients (n = 45) had type 2 diabetes, and 30% of patients (n = 27) had drug-induced diabetes. A total of 39% (n = 29) had poorly controlled diabetes with HbA1c > 9% (75 mmol/mol). In patients with known type 1 diabetes, the most common provoking factors were inadequate insulin therapy and infection related causes. In patients with known type 2 diabetes or no previous history of diabetes, the most common provoking factors were medications such as immune checkpoint inhibitors, SGLT2 inhibitors and steroids. Conclusions: We characterized the precipitating factors for DKA based on patients’ underlying diabetes status. While insulin non-adherence was the most common cause in patients with known type 1 diabetes, drugs associated with cancer related treatments emerged most common precipitating factor for DKA in cancer patients with underlying type 2 diabetes or drug induced diabetes. A tailored approach with proactive counseling may be helpful in timely recognition and treatment of DKA in cancer patients.


13 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MAMohamed E. Abdelsalam
Mohamed E. Abdelsalam
AAAhmed Awad
Ahmed Awad
RRRobert J. Raymond
Robert J. Raymond
ZWZhongya Wang
Zhongya Wang
DIDavid C Irwin
David C Irwin
KAKamran Ahrar
Kamran Ahrar
Objective: To assess the long-term oncologic and survival outcomes of percutaneous cryoablation (PCA) for patients with solitary de novo T1a renal cell carcinoma (RCC). Methods: This retrospective study was conducted following the STROBE guidelines. We included patients with a single, biopsy-confirmed, treatment-naïve T1a RCC (<4 cm) who underwent PCA between January 2008 and December 2021. Patient demographics, tumor characteristics, and procedural details were collected. Survival analyses were performed using the Kaplan–Meier estimator. Results: Eighty-six patients (57 men and 29 women) with a median age of 69 years met the inclusion criteria. Fifty patients (58%) had a history of an additional non-renal malignancy. In total, 86 renal tumors were treated using PCA, with a median tumor diameter of 2.7 cm. Clear cell RCC accounted for 67.4% of the tumors. Procedural complications classified as Clavien–Dindo grade III or higher occurred in 4.6% of cases. Local tumor recurrence at the ablation site was observed in five patients (5.8%), and four patients (4.6%) developed new lesions elsewhere within the kidney. The estimated median overall survival was 10.34 years. The 10-year local recurrence-free and disease-free survival rates were 93.5% and 84.0%, respectively. Both metastasis-free survival and cancer-specific survival rates at 10 years were 100%. Conclusions: Percutaneous cryoablation provided durable local tumor control with low major morbidity and favorable long-term oncologic outcomes in this selected cohort of patients with solitary cT1a renal tumors.